Related Experiment Video

Updated: May 29, 2026

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay
08:34

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay

Published on: July 15, 2025

Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving

Vivek Subbiah, Laura S Angelo, Razelle Kurzrock

    Expert Opinion on Investigational Drugs
    |September 23, 2011
    PubMed

    Insights

    Insulin-like growth factor 1 receptor (IGF-1R) inhibitors show promise against tumors. Personalized patient selection using molecular data is key for developing these targeted cancer therapies.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • Insulin-like growth factor 1 receptor (IGF-1R) signaling pathways are implicated in various cancers.
    • IGF-1R inhibitors represent a targeted therapeutic strategy with demonstrated anti-tumor activity.

    Discussion:

    • The development of IGF-1R inhibitors is complex, involving diverse drug candidates and multiple pathway interventions.
    • Effective clinical translation necessitates a deep understanding of the IGF-1R pathway and its modulation by different agents.

    Key Insights:

    • Patient stratification based on molecular profiling and predictive signatures is crucial for optimizing IGF-1R inhibitor efficacy.
    • Matching patients to specific IGF-1R inhibitors based on their tumor's molecular characteristics will enhance treatment outcomes.

    Outlook:

    • Future development hinges on robust biomarker discovery and the integration of molecular profiling into clinical trial design.
    • Advancing targeted cancer therapy requires a personalized approach to IGF-1R inhibitor selection and development.

    More Related Videos

    In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues10:36

    In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

    Published on: March 21, 2017

    Related Concept Videos

    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
    Insulin: The Receptor and Signaling Pathways01:28

    Insulin: The Receptor and Signaling Pathways

    Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Transducer Mechanism: Enzyme-Linked Receptors01:27

    Transducer Mechanism: Enzyme-Linked Receptors

    Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
    Major types that are helpful drug targets include:
    Experimental RNAi02:15

    Experimental RNAi

    RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...